Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
作者： Roy S. Herbst , Giuseppe Giaccone , Joan H. Schiller , Ronald B. Natale , Vincent Miller
关键词: Surgery 、 Necitumumab 、 Medicine 、 Gefitinib 、 Oncology 、 Docetaxel 、 Lung cancer 、 Internal medicine 、 Clinical trial 、 Carboplatin 、 Tolerability 、 Paclitaxel
摘要: … those receiving gefitinib 500 mg/d (Table 4). Similarly, the number of gefitinib dose interruptions and reductions was highest in the gefitinib 500 mg/d arm and similar in the gefitinib 250 …
elsevier.com
utsystem.edu参考文章(30)
Motowo Nakajima, Sen Pathak, Isaiah J. Fidler, Kiyoshi Morikawa, J. Milburn Jessup, Shirley M. Walker, Influence of Organ Environment on the Growth, Selection, and Metastasis of Human Colon Carcinoma Cells in Nude Mice Cancer Research. ,vol. 48, pp. 6863- 6871 ,(1988)
Didier Wion, Philippe Brachet, Neelakanta Ravindranath, Daniel Djakiew, Epidermal Growth Factor Modulates the Expression of Vascular Endothelial Growth Factor in the Human Prostate Journal of Andrology. ,vol. 22, pp. 432- 443 ,(2001) , 10.1002/J.1939-4640.2001.TB02199.X
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara, Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. ,vol. 19, pp. 3210- 3218 ,(2001) , 10.1200/JCO.2001.19.13.3210
D.M Parkin, F.I Bray, S.S Devesa, Cancer burden in the year 2000. The global picture. European Journal of Cancer. ,vol. 37, pp. 4- 66 ,(2001) , 10.1016/S0959-8049(01)00267-2
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
Agapi Kataki, Philippe Scheid, Maud Piet, Beatrice Marie, Nadine Martinet, Yves Martinet, Jean-Michel Vignaud, Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. Journal of Laboratory and Clinical Medicine. ,vol. 140, pp. 320- 328 ,(2002) , 10.1067/MLC.2002.128317
L. J. C. van Warmerdam, S. Rodenhuis, W. W. ten Bokkel Huinink, R. A. A. Maes, J. H. Beijnen, The use of the Calvert formula to determine the optimal carboplatin dosage Journal of Cancer Research and Clinical Oncology. ,vol. 121, pp. 478- 486 ,(1995) , 10.1007/BF01218365
D.M. Parkin, F.I. Bray, S.S. Devesa, Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66] European Journal of Cancer. ,vol. 39, pp. 848- ,(2003) , 10.1016/S0959-8049(02)00739-6